Loading
A phase 2 trial of Abiraterone acetate, Enzalutamide in prostate cancer, run by Novartis Pharmaceuticals, active and no longer recruiting.
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC) is a phase 2 interventional study registered as NCT06991556 by Novartis Pharmaceuticals, with 168 participants enrolled, started 2025-07-07 and due to reach its primary completion in 2032-02-13. Interventions recorded: JSB462, Abiraterone, Enzalutamide. Conditions listed: Metastatic Hormone-sensitive Prostate Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Metastatic hormone-sensitive prostate cancer, Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Novartis, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Novartis, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer.
Shares Metastatic hormone-sensitive prostate cancer, Enzalutamide, Prostate cancer.
Shares Enzalutamide, Novartis, Prostate cancer.
Shares Abiraterone acetate, Enzalutamide, Prostate cancer.
Shares Abiraterone acetate, Prostate cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/